AMN Healthcare Q3 2026: Revenue Jumps 13%, EBITDA Surges to $94M

What happened

AMN Healthcare reported third-quarter 2026 revenue of $717 million, a 13% year-over-year increase that exceeded the low-single-digit growth projected in the prior base case, alongside adjusted EBITDA of $94 million. The GAAP EPS of $0.83 and adjusted EPS of $1.16 reflect a sharp improvement in profitability compared to recent quarters, though the implied adjusted EBITDA margin of 13.1% appears unusually high and may include non-recurring benefits. These results suggest that the cyclical recovery in nurse and allied staffing demand, a key pillar of the investment thesis, is materializing faster than expected, potentially supporting a higher valuation than the $22 base-case target. However, the press release lacks segment-level detail and gross margin data, making it difficult to confirm whether the earnings quality is durable or inflated by one-time factors such as strike revenue or cost deferrals. Investors should treat the strong headline numbers with cautious optimism until the full 10-Q filing clarifies the drivers of the EBITDA beat.

Implication

The 13% revenue growth and $94 million adjusted EBITDA indicate that AMN's core staffing demand has inflected upward, likely driven by persistent clinician shortages and improved hospital spending, which is well above the prior base-case assumptions. This performance supports a higher intrinsic value than the $22 base case, potentially moving the stock toward the $25-$30 range if the margin improvement is structural. However, the adjusted EBITDA margin of 13.1% is roughly double the company's recently guided trough margin, and without segment details it could reflect temporary factors like strike work or cost deferrals that may not repeat. Investors should confirm in the upcoming 10-Q whether the margin expansion is driven by durable mix shifts toward higher-margin technology and international solutions or by non-recurring items. Given AMN's elevated leverage and historical volatility, position sizing should remain disciplined, and a re-rating should be contingent on sustained evidence of volume growth and margin stability.

Thesis delta

The original thesis positioned AMN as a potential buy based on early signs of stabilization and gradual recovery. The Q3 2026 results materially strengthen the bull case, showing confirmed revenue growth and a sharp EBITDA beat that suggests the recovery is ahead of schedule. However, the lack of segment detail and the unusually high margin raise questions about earnings quality, so the thesis shifts from 'stabilization' to 'recovery with validation needed'.